FDA Breakthrough Device Designation (BDD) is one of the most powerful regulatory tools available to MedTech innovators today. It grants priority FDA interaction, streamlined clinical pathway guidance, and a clear signal to investors and payers that your device addresses a significant unmet clinical need. In 2026, a new Medicare coverage pathway—RAPID—makes this designation more valuable than ever.

This article explains what Breakthrough Device Designation is, who qualifies, what comes after designation, and how Meditrial’s integrated regulatory and clinical expertise helps companies navigate every step from opportunity assessment to market authorization.

• 1,246 Breakthrough designations granted since 2015
• 185 Devices reached FDA market authorization
• ~160 Designations awarded in 2025
• 60–90 Days to Medicare coverage under RAPID

Sources: FDA CDRH (Dec 31, 2025); CMS/FDA RAPID announcement (Apr 23, 2026).

FDA Breakthrough Device Designation is a voluntary program that accelerates the development and review of medical devices offering more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. Designated companies receive priority FDA review, enhanced regulatory interaction, and flexible clinical study designs to speed patient access.

Established by Congress through the 21st Century Cures Act, the Breakthrough Devices Program has become the FDA’s most established expedited device pathway. To qualify, a device must treat or diagnose a serious condition and meet at least one of four criteria, such as representing a meaningful clinical advantage over existing alternatives or addressing a condition with no approved options.

The program continues at a steady pace. The FDA is on track to grant approximately 168 designations in fiscal year 2026—consistent with the 164–166 range seen in 2022 through 2025. The top therapeutic areas remain cardiovascular, neurology, and orthopedics, with cardiovascular consistently leading. That means competition for designation is real, and the quality of your submission matters.

Beyond speed, designation delivers three strategic advantages:

• Accelerated FDA engagement: Priority interaction and review with FDA experts shortens alignment timelines on clinical and regulatory strategy.
• Optimized development pathway: Earlier guidance on endpoints, study design, and evidence thresholds reduces costly late-stage pivots.
• Investor and market confidence: BDD signals innovation and addresses significant unmet clinical need—two messages that resonate with investors, hospital systems, and payers alike.

Navigating from an unproven concept to FDA authorization requires a coordinated strategy. Here is the Meditrial framework for moving through the Breakthrough journey efficiently:

Achieving BDD is not the finish line—it is the starting line for a structured, proactive regulatory strategy. Two critical programs define what happens next.

What TAP Does
TAP provides early and continuous FDA engagement across the full product lifecycle. It enables cross-functional collaboration, reduces regulatory uncertainty, and aligns evidence generation from early development through post-market—making it a natural complement to Breakthrough designation.
TAP’s lifecycle-oriented advisory approach helps companies anticipate regulatory expectations rather than react to them. For cardiovascular and other high-complexity breakthrough technologies, this proactive alignment can shave months off the development timeline.

The single most significant development for Breakthrough Device companies in 2026 is the launch of the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, jointly announced by CMS and FDA on April 23, 2026.

Why RAPID Changes the Equation

Before RAPID, the gap between FDA authorization and Medicare national coverage—sometimes called the “valley of death”—routinely stretched beyond a year, leaving innovators with authorized devices and no reimbursement pathway. Under RAPID, CMS will issue a proposed national coverage determination on the same day a qualifying device receives FDA authorization, enabling Medicare coverage within 60 to 90 days of approval. Approximately 40 currently designated devices qualify for the pathway, with 20 more potentially eligible.

RAPID works by embedding CMS into the development process far earlier—during the investigational phase—so the evidence generated for FDA premarket review simultaneously supports Medicare coverage decisions. This parallel alignment eliminates the traditional sequential approach where companies only engaged CMS after FDA authorization.

Most regulatory consultancies and CROs operate in silos—strategy here, clinical operations there, data elsewhere. Meditrial was built differently. As a Digital Research Organization (DRO), Meditrial integrates regulatory strategy, clinical execution, and global evidence generation into a single, cohesive framework designed specifically for innovative medical devices.

That integration is what makes the difference at every inflection point of the Breakthrough journey:

• Deep regulatory expertise across Breakthrough Device Designation, IDE, De Novo, 510(k), and PMA pathways.
• Extensive cardiovascular and structural heart experience, the leading area for Breakthrough designations.
• Global clinical development with US and international site execution, enabling studies that satisfy both FDA and international regulatory bodies simultaneously.
• Integrated expert team spanning regulatory affairs, clinical operations, biostatistics, imaging, and quality assurance under one roof.
• Inspection-ready processes and a quality-driven culture built for the scrutiny breakthrough devices attract.
• AI-enabled digital infrastructure through the Medigen Suite—EDC, eConsent, eSource, and CTMS—powering risk-based monitoring, data integrity, and accelerated timelines.

Innovation moves faster when regulatory strategy, clinical evidence, and operational execution function as one integrated system—not three separate workstreams handed off sequentially.

Breakthrough Device Designation is a voluntary FDA program that expedites development, assessment, and review of devices offering meaningful advances in treating life-threatening or irreversibly debilitating conditions. As of December 2025, the FDA had granted 1,246 designations since the program launched in 2015.

As of December 31, 2025, the FDA granted 1,246 Breakthrough Device designations. Of those, 185 have gone on to receive FDA marketing authorization—a number that demonstrates both the program’s momentum and the real regulatory work required to reach market.

Key benefits include priority FDA review and interaction, earlier alignment on clinical and regulatory strategy, flexible study designs (including surrogate endpoints and smaller study populations where scientifically justified), and stronger positioning with investors and payers. Designation also enables access to the FDA TAP program and, in 2026, qualifies devices for the new RAPID Medicare coverage pathway.

The Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, announced jointly by CMS and FDA on April 23, 2026, aligns FDA premarket review and Medicare national coverage decisions so that qualifying breakthrough devices can receive Medicare coverage within 60 to 90 days of FDA authorization—compared to more than a year under the previous process. CMS engages with device manufacturers during clinical development rather than after authorization, allowing a unified evidence strategy.

Cardiovascular, neurology, and orthopedics are consistently the top three. Cardiovascular remains the leading area overall, with Meditrial’s deep structural heart and cardiovascular experience making it a particularly strong partner for companies in that space.

Meditrial provides end-to-end support: from initial opportunity assessment and BDD request preparation through early FDA interaction, clinical study design and execution, regulatory submissions, and post-authorization support. The integrated team—regulatory, clinical, biostatistics, imaging, and quality—operates under one framework designed to minimize handoffs and maximize development speed.

One Partner. Integrated Solutions. Faster Pathways. Better Outcomes.